Clonidine for anticipatory nausea and vomiting: A pilot study examining dose-toxicity relationships and potential for further study

J. H. Fetting, V. R. Sheidler, M. E. Stefanek, J. P. Enterline

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

In preparation for studies of noradrenergic activity in anticipatory nausea and vomiting, we performed an open-dose study of clonidine to examine dose-toxicity relationships and indications of antiemetic activity. Nine patients, three each at 0.1, 0.2, and 0.4 mg/day, received clonidine twice a day for 5 days before chemotherapy. Unwanted effects, principally blood pressure reduction, dry mouth, and sedation, accumulated between 4 and 5 μg/kg/day. Four of eight evaluable patients had no anticipatory symptoms on clonidine. It is concluded that clonidine, at a dose of 4 μg/kg/day, might safely probe the role of noradrenergic activity in anticipatory nausea and vomiting.

Original languageEnglish (US)
Pages (from-to)409-410
Number of pages2
JournalCancer Treatment Reports
Volume71
Issue number4
StatePublished - Jan 1 1987

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Clonidine for anticipatory nausea and vomiting: A pilot study examining dose-toxicity relationships and potential for further study'. Together they form a unique fingerprint.

  • Cite this